INGAP peptide comprises the core active sequence of Islet Neogenesis Associated Protein (INGAP), a pancreatic cytokine that can induce new islet formation and restore euglycemia in diabetic rodents. The ability of INGAP peptide in vitro to enhance nerve growth from sensory ganglia suggests its potential utility in peripheral nerve disorders. In this study, INGAP peptide was administered alone or in combination with insulin to streptozotocin-induced diabetic mice exhibiting signs of peripheral neuropathy. Following a 2-wk treatment period, thermal hypoalgesia in diabetic mice was significantly improved in groups that received INGAP peptide, without development of hyperalgesia. Explanted dorsal root ganglia (DRG) from these groups showed enhanced nerve outgrowth and evidence of increased mitochondrial activity. Western blotting experiments revealed attenuation of neurofilament hyperphosphorylation, up-regulation of β-tubulin and actin, and increased phosphorylation of the transcription factor STAT3 in DRG. These findings suggest that INGAP peptide can activate some of the signaling pathways implicated in nerve regeneration in sensory ganglia, thereby providing a means of improvement of nociceptive dysfunction in the peripheral nervous system. Key words: dorsal root ganglia • diabetic neuropathy • STAT mong the complications of diabetes, peripheral neuropathy (DN) remains arguably the most debilitating and has presented a major challenge to the development of effective therapeutics (1, 2). The general consensus is that therapy with insulin (3, 4) or with the classical neurotrophins nerve growth factor (NGF) (5) or brain-derived neurotrophic factor (BDNF) (6) is largely ineffective as treatment for this disorder. Recent efforts have focused on other growth factors, including neurotrophin-3 (NT-3) (7, 8) , glial-derived neurotrophic factor (GDNF) (9, 10), and insulin-like growth factor 1 (IGF-1) (11-13), whose modes of action in nervous tissue are well defined. More recently, neuroprotective properties of the insulinotropic agents glucagon-like peptide 1 (GLP-1) and its analog exendin-4 have been identified (14) (15) (16) (17) , and their combined pancreatic and neural effects may make them potentially useful as leads for the development of therapeutics for DN. The ability of the islet neogenic agent INGAP peptide to exert neurotrophic influence on sensory ganglia in vitro (18) prompted us to examine its effects on nociceptive dysfunction in experimental diabetic neuropathy.
to exert neurotrophic influence on sensory ganglia in vitro (18) prompted us to examine its effects on nociceptive dysfunction in experimental diabetic neuropathy.
INGAP was originally identified as a growth factor expressed in partially obstructed pancreata that is capable of inducing the formation of new islets of Langerhans (19) (20) (21) and the normalization of hyperglycemia in diabetic rodents (22) (23) (24) . The expression of INGAP in human and normal rodent pancreata (25) suggests that the protein may have multiple functions. Of particular relevance to the nervous system, INGAP shares close homology with the Reg gene family (19, 26) , whose members are involved in the regeneration of sensory (27) and motor (28, 29) neurons, as well as in the formation of new β cells (30) . Our finding that INGAP peptide can enhance nerve growth in axotomized sensory ganglion cultures (18) suggests a potential role in the process of nerve regeneration. However, little is known about the mechanism of action of INGAP peptide in the nervous system, although an indirect effect on neurons via increased production of neurotrophic factors from nonneuronal cells has been proposed (18) .
A requisite for successful sensory nerve regeneration following injury under normal conditions is initial Wallerian degeneration, which encompasses several cellular events (reviewed in ref 31 and 32) . Damaged axonal debris is cleared by infiltrating macrophages, and cytokines released from macrophages trigger Schwann cells to switch from a program of myelin maintenance to one of mitosis and proliferation. Migrating Schwann cells contribute to the pathways later followed by newly extending axons and likely provide trophic support for the regenerating neurons. As nerve degeneration proceeds, nerve regeneration begins with changes in neuronal gene expression, including up-regulation of β-tubulins and down-regulation of neurofilament (NF) proteins (33). Extending sensory axons re-innervate peripheral targets through guidance mechanisms that are not entirely clear, although the regenerative process in the mature sensory nerve is an NGF-independent one (34, 35) that appears to utilize the Janus kinase (JAK)-STAT pathway and not mitogen-activated protein kinase (MAPK) or phosphoinositide-3-kinase (PI3K)-Akt-mediated signal transduction (36) . Functional maturation of the regenerated sensory nerves involves myelination and increased NF expression and phosphorylation, key determinants of axonal caliber and thus nerve conduction velocity (37) and axonal transport (38) , processes in which numerous kinases are implicated, including extracellular regulated kinase (ERK) (39) , cJun N-terminal kinase (JNK) (40, 41) , and cyclin-dependent kinase 5 (CDK5) (42, 43) .
In the diabetic peripheral sensory nervous system, defects exist at numerous levels in the regeneration process, and each represents a potential point of therapeutic intervention. A prominent finding in diabetes has been the abnormalities in MAPK activity in the sensory ganglia and axons in diabetes (44) , and it has been proposed that MAPKs act as centralized transducers of the numerous metabolic derangements that occur in diabetes (45). Whether pharmacological manipulation of these kinases in vivo will prove beneficial in diabetic neuropathy remains to be seen. Because maintenance of nerve function remains a primary objective in treating peripheral neuropathy, modulation of the signal transduction pathways directly involved in the regrowth of mature nerves is an attractive approach. We have examined the in vivo effects of the pancreatic cytokine INGAP peptide on several measures of experimental diabetic neuropathy and here report on a JAK-STAT pathway as a component in the mechanism of action of INGAP peptide.
MATERIALS AND METHODS

Generation and monitoring of diabetic mice
Diabetic mice were generated according to the multiple low-dose streptozotocin protocol (46). Briefly, naïve C57BL/6 male mice (Charles River Laboratories, Wilmington, MA) of 1 month of age were given a single i.p. injection of either streptozotocin (STZ) (Sigma-Aldrich, Oakville, ON, Canada) at a dose of 40 mg/kg or of an equivalent volume of citrate buffer vehicle for five consecutive days. Blood glucose levels were assessed by tail-vein method using a Precision QID meter (Medisense, Abbott Laboratories, Mississauga, ON, Canada). Mice that did not exhibit hyperglycemia at this time were given an additional one or two injections of STZ on separate days, as necessary for hyperglycemia to develop. Mice were housed in approved animal care facilities on a 12 h light/dark cycle and given ad libitum access to food and water. Mice were weighed on an electronic balance, and blood glucose was assessed once wkly for 3 months following induction of diabetes. All efforts were made to minimize unnecessary discomfort to the animals in accordance with the university guidelines on ethical treatment of research animals.
Administration of INGAP peptide and insulin
INGAP peptide (Sheldon Biotechnology, Montreal, QC, Canada) was prepared in sterile phosphate-buffered saline (PBS) to deliver a dose of 25 mg/kg of mouse body weight via i.p. injection in control and diabetic mice. Matching control groups received an equivalent volume of PBS vehicle. Injections were started at the end of the 3-month diabetes induction period, and given once per 2 days for a 14-day period. Insulin was administered by subcutaneous LinBit implants for mice (LinShin, Toronto, ON, Canada). Each implant continuously delivered 0.1 U of insulin per day, and dosage was adjusted for mouse body weight according to the manufacturer's directions. Surgical implantation under the skin at the base of the neck was performed after 3 months of diabetes induction. The effectiveness of the implants was determined by measuring blood glucose levels the day after surgery was performed.
Sensory testing
Heat nociception assays were performed based on the method originally described by Woolfe and MacDonald (47). After habituation to the test environment and the handler, mice were placed on an aluminum surface maintained at 54.0 ± 0.2°C on a Dry Bath Incubator (Fisher Scientific, Nepean, ON, Canada). Locomotion was restricted to a 10 × 10 cm area by a 15 cm high glass wall enclosure, and an observer monitored for the first response indicative of nociception (sustained hindpaw lift, hindpaw lick, or hindpaw shake/flutter), measured with a timer and recorded to the nearest 0.1 s. The time to response defines the withdrawal latency. The cutoff time for latency to withdrawal was set at 45 s. Due to the obvious differences in size and appearance between the naïve mice and 3-month diabetic mice, the observer could not be blinded with respect to diabetes; the observer was, however, blinded to treatment group. Three latencies per animal were obtained from assays spaced 5 min apart. Baseline withdrawal latencies were obtained from mice before diabetes induction, after the 3-month diabetes induction period but before treatment, and at 2 or 4 day intervals after the start of treatments. Tail-flick assays were performed using an experimental design similar to that of the hot-plate assays. The tails of restrained mice were immersed in a water bath maintained at 54.0 ± 0.2°C, and the monitored response was a curling of the tail. A cutoff latency of 20 s was used. On days when both an injection and a sensory test in the same mice were scheduled, the mice were injected after the completion of the testing.
Motor testing
Preliminary studies of motor function were done to discover whether this was impaired in the diabetic animals. Motor function was assessed using assays based on the grasping test described by Bertelli (48) and the walking track test reported by Varejao (49).
Explant cultures and nerve growth
On the day of sacrifice, mice were anesthetized with ketamine/xylazine/acepromazine method and decapitated by rodent guillotine in accordance with approved standard operating procedures of the local animal care committee. The third, fourth, and fifth pairs of lumbar dorsal root ganglia (DRG) and sciatic nerves were dissected. For explant culture experiments, DRG were embedded in Matrigel matrix (BD Biosciences, Mississauga, ON, Canada) and cultured in RPMI-1640 media containing 1% antibiotic solution (Invitrogen, Burlington, ON, Canada) in six-well tissue culture dishes (Falcon, VWR Canlab, Town of Mont-Royal, QC, Canada). Cultures were maintained at 37°C with 5% CO 2 for either 1 or 2 wk after plating, with media changes every 2 days. Images of nerve growth (total neuritic density, maximum length) were captured with a light microscope attached to an MCID/M4 image analysis system (Imaging Research, St. Catharines, ON, Canada) and stored in uncompressed tagged image file format (TIFF) at a resolution of 600 d.p.i. Total neuritic density was assessed with a method modified from that of Bilsland et al. (50) . Briefly, in Adobe Photoshop 6.0, density thresholding was used to isolate the neuritic portion of the image from the cell body portion, and the density of the neuritic area was measured using NIH Image software. The neuritic density values were then divided by the area of the cell body portion to account for differences in ganglion size. The greatest extent of outgrowth was analyzed using the line tool of NIH Image, calibrated to images of a microscope calibration slide.
Assessment of mitochondrial activity
DRG were cultured as described for nerve growth experiments. The yellow tetrazolium salt MTT ([3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl] tetrazolium bromide) is cleaved to give purple formazan crystals by mitochondrial dehydrogenases, which are active only in metabolically intact cells. Increased MTT conversion is a measure of increased cellular metabolic activity and can reflect increased cell number (18, 51, 52). After either 1 or 2 wk in culture, MTT (SigmaAldrich) dissolved in sterile PBS was added to the culture media at a concentration of 1.2 mM for 2 h as described previously (18) . Briefly, media were then aspirated and DRG were incubated in 250 µl of DMSO for 1 h. DMSO (100 µl) from each culture was transferred to a 96-well plate, and absorbance at 595 nm was read using a Bio-Rad (Mississauga, ON, Canada) Benchmark plate reader.
Gel electrophoresis and Western blotting
For Western blotting experiments, dissected DRG were lysed separately on ice in lysis buffer (50 mM Tris, 140 mM NaCl, 17 mM Nonidet P-40, 1.09 M glycerol, pH 8.0, 10 mM vanadate, and one tablet Complete Protease Inhibitor Cocktail [Roche, Laval, QC, Canada]) for 20 min followed by sonnication on ice (3×5 s) and centrifugation at 14,000 rpm for 5 min at 4°C. The supernatants were collected, and protein concentration was determined using Bio-Rad protein assay reagent. Sample buffer, ×6 (1.5 M Tris-HCl, pH 6.8, 10% SDS, glycerol, bromophenol blue, 2-mercaptoethanol in ddH 2 O) was added to the remaining lysates, and the samples were boiled for 4 min at 100°C. Lysates were stored at -20°C until time of electrophoresis. Equivalent amounts of protein were loaded onto 12% SDS-polyacrylamide gels and separated by electrophoresis (Bio-Rad, 100 V). Proteins were transferred to nitrocellulose membranes (BioRad, 250 mA), which were then blocked with 0.1% bovine serum albumin in TBS+T (20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20) for 24 h. Separated proteins were visualized on gels by Coomassie staining, and Ponceau red staining was used to assess the relative band intensity of transferred proteins on the membranes. Primary antibodies to p-STAT3 (1:1000, Cell Signaling, Beverly, MA), STAT3 (1:1000, Cell Signaling), p-NF-H (1:800, Sternberger, Lutherville, MD), NF-H (1:800, Sternberger), NF-L (1:1000, Zymed, San Francisco, CA), actin (1:1000, Chemicon, Temecula, CA), β-III-tubulin (1:1000, Chemicon), p-ERK (1:5000, Promega, Madison, WI), ERK (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA), p-Akt (1:1000, Cell Signaling), Akt (1:1000, Cell Signaling), p-JNK (1:5000, Promega), JNK (1:1000, Promega), and CDK5 (1:1000, Chemicon) were applied at the suppliers' recommended dilutions to membranes for 24 or 48 h, followed by several washes with TBS+T. Membranes were incubated with HRP-conjugated secondary antibodies (goat anti-rabbit; sheep anti-mouse, 1:4000, Amersham Biosciences, Baie d'Urfe, QC, Canada) for 1 h, followed by several washes with TBS+T. Immunoreactive bands were detected using ECL detection system (Amersham Biosciences) and Kodak (Rochester, NY) X-Omat-Blue film, and films were scanned at 600 d.p.i. with a Umax Astra scanner. Bands were quantified and analyzed with MCID/M6 image analysis software (Imaging Research, St. Catharines, ON, Canada).
Statistical analysis
Significant differences between treatment groups were assessed with Systat 10 software using two-way ANOVA with post hoc Dunnett's test or Tukey's test where appropriate. Differences were considered significant when P < 0.05.
RESULTS
INGAP peptide corrects thermal hypoalgesia in diabetic mice without inducing hyperalgesia and without additivity or synergism with insulin
Sensory testing results from hot-plate assays are shown in Figure 1 . Baseline response latencies ( Importantly, INGAP peptide administration in nondiabetic, control mice did not produce hyperalgesia as no significant changes in response latency occurred relative to nontreated nondiabetic mice (Fig. 1A , NS, P>0.05). In diabetic mice, however, INGAP peptide and/or insulin administration had varying effects on response latencies, which are presented separately for ease of comparison. Figure To assess whether motor function was impaired in the diabetic animals in this study, we used the grasping test described by Bertelli (48) and the walking track test reported by Varejao (49). The results showed no impairment of motor function and no effect of INGAP peptide on these functions (not shown).
Reestablishment of normoglycemia by INGAP peptide is not achieved by short-term administration
Blood glucose levels and body weights of the treated groups and age-matched controls are shown in Table 1 . Diabetic mice exhibited marked weight loss (48%, P<0.05) and hyperglycemia (22.0±2.4 mmol/dl) characteristic of insulin-dependent diabetes mellitus (IDDM). Neither parameter was improved by 2 wk of INGAP peptide treatment. Insulin-receiving groups were normoglycemic, but insulin administration alone or in combination with INGAP peptide did not reverse weight loss in the diabetic groups at the end of the 2-wk treatment period.
INGAP peptide administered in vivo enhances nerve regenerative capacity examined in vitro
DRG were dissected at the end of the 2-wk treatment period and cultured as primary tissue explants in the absence of media supplements. In the process of culture preparation, DRG neurons become axotomized and the culture system thus serves as a model of nerve regeneration in vitro (53). Nerve growth was monitored for a period of 1 wk and assessed as either total neuritic density ( Fig. 2A) or maximal length (Fig. 2B) . Discernable outgrowth was first observed after 1-2 days in culture. After 4 days, outgrowth from the nontreated diabetic group was most pronounced, a somewhat unexpected finding given the reported impairment of regeneration in vivo (see, e.g., ref 54-56) ( Fig. 2A, Day 4) . However, this outgrowth underwent a rapid decline over the next 3 days; during this period, the outgrowth in the nontreated control group was significantly increased ( Fig. 2A, Day 7) . By 7 days in culture, outgrowth in DRG from all the groups (nondiabetic and diabetic) treated in vivo with INGAP peptide was significantly greater than nontreated control groups ( Fig. 2A, Day 7) , with the greatest outgrowth occurring in DRG from diabetic mice treated with INGAP peptide (Fig. 2A, 2C ) or with the combination of INGAP peptide and insulin (Fig. 2B) . Insulin treatment alone resulted in DRG outgrowth that was less robust than that resulting from INGAP peptide treatment, although greater than the nontreated diabetic group (Fig. 2B) .
INGAP peptide induces signal changes characteristic of nerve regeneration
Dorsal root ganglia were dissected at the end of the 2-wk treatment period, and samples were prepared for Western blotting. Nerve regeneration is associated with changes in the expression of a number of structural proteins, including neurofilaments, tubulins, and actin. The heavy neurofilament subunit (NF-H) is known to be hyperphosphorylated in the DRG in experimental diabetes, an observation we confirmed in our diabetic mice (Fig. 3A) . In the DRG from diabetic mice treated with INGAP peptide, the amount of phosphorylated NF-H (p-NF-H) was markedly reduced. A minor increase in p-NF-H levels was observed in nondiabetic mice treated with INGAP peptide. These changes occurred in the absence of changes in the expression of NF-H (Fig. 3A) , or that of NF-L (not shown). We then assessed the expression levels of β-III-tubulin and actin. β-III-tubulin expression was similar in nontreated control and diabetic mice (Fig. 3A) , and INGAP peptide administration led to an increase in β-III-tubulin expression in both groups. The expression levels of actin were similar in all groups (C, C+IG, D), except for INGAP peptide-treated diabetic mice, in which a small up-regulation of actin was observed (29%, Fig.  3C , P<0.05).
Major signal transduction pathways implicated in regenerative nerve growth include the ERK, PI3K-Akt, and JAK-STAT pathways. We examined the activation and expression levels of these proteins and found that the ERK (as well as JNK) and PI3K-Akt pathways were largely unaffected by INGAP peptide administration in nondiabetic and diabetic animals after the 2-wk treatment period (not shown). However, phosphorylation of the transcription factor STAT3, while barely detectable in DRG from nontreated control and diabetic mice, was significantly increased by INGAP peptide in both groups (Fig. 3B) . The latter phenomena are currently being further investigated. The expression of cyclin-dependent kinase 5 (CDK5), which has not been reported to be altered in the DRG in diabetic neuropathy, was not significantly different between the treatment groups and is provided in Figure 3B as a loading control. Quantitation of the proteins affected by INGAP peptide treatment are presented in Figure 3C .
INGAP peptide administered in vivo enhances mitochondrial activity of sensory ganglia in vitro
MTT assays, which directly measure mitochondrial activity (enzymatic conversion of MTT to formazan), are also used to assess relative cellular metabolic activity and can reflect changes in cell number (18) . An impaired mitochondrial function has been reported in diabetic neuropathy (57). In dorsal root ganglia explants cultured for 7 days, MTT assays indicated that DRG cell mitochondrial activity in nontreated diabetic mice was markedly reduced as compared with control mice (30%, P<0.05) (Fig. 4) . INGAP peptide administration led to significant increases in formazan formation in both nondiabetic (25%, P<0.05) and diabetic mice (30%, P<0.05) in comparison to their respective nontreated controls. The DRG metabolic activity in diabetic mice treated with INGAP peptide was restored to that of normal (nontreated) control mice. The combination of INGAP peptide and insulin administration in diabetic mice did not enhance DRG mitochondrial activity beyond that observed with INGAP peptide treatment alone (Fig. 4) . Insulin treatment alone was without effect on cell mitochondrial activity in comparison with nontreated diabetic mice.
DISCUSSION
Results from these studies provide the first evidence that INGAP peptide can exert effects in vivo on the sensory nervous system in mice. We used the streptozotocin-induced model of diabetes to evaluate the effects of INGAP peptide on established peripheral neuropathy, and we found overall that treatment improved functional and biochemical measures of the neuropathic condition.
INGAP peptide corrects thermal hypoalgesia in diabetic mice without inducing hyperalgesia and without additivity or synergism with insulin
The behavioral tests conducted in this study indicate that the primary sensory defect in the diabetic mice was manifest as thermal hypoalgesia and that motor function defects were absent from the experimental groups. In the streptozotocin-induced model of diabetes, reports of thermal nociceptive thresholds have been highly variable with hypoalgesia, hyperalgesia, or no algesia reported by a number groups as discussed by Fox et al. (58); more recently, Calcutt and Tomlinson reported hypoalgesia following 10 wk of diabetes in a large-scale study involving streptozotocin-induced diabetic rats (59) . Few reports address the specific type of thermal algesia in streptozotocin-induced diabetic mice. One study reported thermal hyperalgesia in mice 1 wk following induction of diabetes by high-dose streptozotocin injection (60) . We observed hyperalgesia in diabetic mice at 1 month postinduction of diabetes that progressed to hypoalgesia at 3 months, which agrees with the time-dependent switch in sensory dysfunction reported by Kolta et al. in streptozotocin-induced diabetic rats (61) . However, regardless of the type of thermal algesia, both sensory dysfunctions point largely to a defect in the subpopulation of small TrkA-expressing nociceptive neurons that respond to NGF and release substance P (SP) and calcitonin gene-related peptide (CGRP) (62) . Our behavioral data suggest that INGAP peptide could act (either directly or indirectly) on this subpopulation of small sensory neurons to correct the observed hypoalgesia (Fig. 1B) . In addition, in vivo administration of INGAP peptide to either diabetic or control mice does not lead to the development of hyperalgesia (Fig. 1A) , as was frequently observed upon administration of NGF in clinical trials to patients with diabetic neuropathy (5, 63) or with other peripheral neuropathies (64) and to a lesser extent in the clinical trials of BDNF for diabetic neuropathy (6).
We found that insulin administration by subcutaneous implantation in diabetic mice was minimally effective in improving response latencies in our thermal sensory testing (Fig. 1C) . In addition, we failed to observe any additive or synergistic effect of INGAP peptide and insulin coadministration on thermal hypoalgesia (Fig. 1D) . These findings could be expected given the short duration of insulin administration (2 wk) relative to the longer treatment periods (4-7 wk) reported to be effective in normalizing hypoalgesia in streptozotocin-induced diabetic rodents (58, 61). Insulin has been shown to exert effects on the nervous system in both direct and indirect manners. The neurite outgrowth-promoting properties of insulin in sensory neurons reported by Fernyhough et al. were shown to involve up-regulation and stabilization of the mRNA for the structural proteins tubulin and neurofilament (11) . The idea of a direct action of insulin in sensory neurons was strengthened by the identification of preferential expression and localization of insulin receptors within sensory ganglia to small-diameter nociceptive neurons (65) that classically express TrkA receptors and are responsive to NGF. It was thus proposed that insulin and NGF signaling in small-diameter neurons is necessary for normal nociceptive function and perhaps for proper myelination and nerve regeneration (65, 66) . However, given the demonstration that the latter, regeneration of mature sensory nerves, is essentially an NGFindependent process (34, 35), a more likely scenario is that insulin also exerts indirect effects on the nervous system through its ability to induce the production of IGF-1 as observed in sural nerve biopsies of diabetic patients (67) . IGF-1 can promote neurite outgrowth from explanted sensory ganglia (68) and in cultures of sensory neurons (11) and other neuronal cell types (69), possibly through mechanisms involving MAPKs and PI3-kinase (69, 70) . Furthermore, IGFs have been shown to reverse hyperalgesia in streptozotocin-induced diabetic rats in spite of persisting hyperglycemia and weight loss (13) . This latter report and our finding that INGAP peptide is effective in correcting thermal hypoalgesia in spite of persisting hyperglycemia and weight loss (discussed below) leads us to hypothesize that INGAP peptide exerts its insulinindependent effects on thermal nociception by enhancing the production of IGF-1 in diabetic mice (unpublished observations), in addition to the increased production of other as yet unindentified trophic factors.
Reestablishment of normoglycemia by INGAP peptide is not achieved by short-term administration
The short-term INGAP peptide dosing regimen used in this study did not effect a reduction in blood glucose levels or an increase in body weight in the diabetic mice (Table 1) . Longer-term in vivo administration of INGAP peptide on a more frequent basis can reverse hyperglycemia in diabetic rodents (22, 71) , and normalization of body weight by insulin implants in streptozotocin-induced diabetic rodents is typically observed only after 3-4 months of treatment (58, 72) . After a relatively short-term 2-wk treatment with INGAP peptide, hyperglycemia in our diabetic mice remained unchanged. Thus, the abbreviated dosing regimen used in this study allowed us to separate the pancreatic effect of INGAP peptide from direct effects of the peptide on peripheral nervous tissue in vivo, as we previously hypothesized (18) . Although we did not directly assess serum insulin levels, the normalization of blood glucose levels observed in insulin-treated diabetic mice indicated that the diabetic groups were normally responsive to insulin. In summary, the changes we observed at the behavioral, morphological, and biochemical levels, in spite of persisting hyperglycemia, can be ascribed to actions of INGAP peptide on the peripheral nervous tissue that are not additive or synergistic with insulin.
INGAP peptide administration in vivo improves nerve regenerative capacity in vitro
The results from the DRG outgrowth assays show that INGAP peptide administration in vivo led to greater process extension in vitro in both diabetic and nondiabetic mice DRG neurons ( Fig. 2A ). In the process of explant culturing, these neurons become separated from their axonal processes, and the culture system thus serves as an in vitro model of axotomy (53). Nerve growth can be classified into one of two major modes, collateral sprouting or regeneration, with the former concerned with the plasticity and maintenance of sensory fields subserved by uninjured nerves (73) and the latter primarily associated with reparative outgrowth following injury (34). Thus, we interpret the results from the explant culture assays as relative capacity for regenerative nerve growth. This view is supported by morphological observations of predominantly elongating nerve outgrowth (Fig. 2C) vs. the highly branched outgrowth typically observed upon NGF treatment of mature DRG in vitro. A transcription-dependent switch that controls arborization and elongation remains to be identified (74) .
The finding of enhanced in vitro nerve outgrowth in DRG from INGAP peptide-treated control mice ( Fig. 2A) in the absence of effects on sensory function, that is, development of hyperalgesia (Fig. 1A) , deserves some mention. INGAP peptide shares a high degree of homology with the Reg family of genes (19, 26) , which are involved in regenerative processes in the pancreas (30) as well as in sensory (27) and motor (28, 29) nerves. Reg gene products, of which Reg2 is expressed solely in the nervous system (29) , act through a family of Reg receptors (75) . We have hypothesized a mechanism of action of INGAP peptide involving activation of Reg2 receptors (18) . The Reg2 protein is not normally expressed in sensory ganglia (27, 29) but is rapidly upregulated in sensory neurons after axotomy (27) . If Reg2 receptors, presumably located on Schwann cells (29) , undergo an injury-dependent expression similar to that of Reg2 protein expression in neurons, this could explain the apparent lack of effect of INGAP peptide treatment on sensory function in healthy, intact nondiabetic mice. Sensory ganglia in diabetic mice are generally considered to be in a state of injury and in a state of failed nerve regeneration, and we are currently investigating the expression of Reg2 in these mice.
INGAP peptide induces signal changes characteristic of nerve regeneration
Nerve regeneration is marked by characteristic changes in the expression of a number of structural proteins. In normal regenerating sensory nerves, the expression of neurofilaments (NFs), a major determinant of axonal diameter (37) , is down-regulated, whereas the expression of β-tubulins is up-regulated (33). In the DRG of diabetic rodents, however, marked hyperphosphorylation of the heavy neurofilament subunit (NF-H) occurs (44) . NF-H tail domain phosphorylation contributes to interfilament spacing and thus functional properties of the nerve, and phosphorylated NF-H (p-NF-H) levels are therefore believed to contribute to peripheral nerve defects in diabetes. We observed a significant decrease in p-NF-H levels in the DRG of diabetic mice treated with INGAP peptide (Fig. 3A) in the absence of changes in NF-H or NF-L expression levels. However, we also observed increases in the expression levels of β-III-tubulin and actin in the DRG of diabetic mice treated with INGAP peptide. β-III-tubulin is up-regulated in extending axonal processes, and actin is a major component of the network on which growth cones advance. Overall, these changes observed in diabetic mice are suggestive of the induction of a program of nerve regeneration by INGAP peptide.
Several signal transduction pathways have been implicated in regenerative nerve growth, including the ERK pathway, the PI3-K/Akt pathway, and the JAK-STAT pathway. Whereas ERK and PI3-K are associated with developmental nerve growth, the JAK-STAT pathway plays a key role in the regenerative growth of mature sensory nerves (36) . More specifically, phosphorylated STAT3 has been implicated in the process of nerve growth following peripheral axotomy (76) or a conditioning lesion (36) . STAT3 expression has been reported in a number of central nervous system and peripheral nervous system structures, including the dorsal root ganglia (77), and we found that the basal expression and phosphorylation of STAT3 was markedly lower in the DRG of diabetic mice as compared with nondiabetic controls. Given the fact that diabetes itself presents the sensory ganglia with serious insult (neuropathy), this finding supports the widely held notion that the intrinsic capacity of the sensory ganglia to respond to insult or injury is reduced. However, we observed that INGAP peptide and/or insulin are effective (albeit to differing degrees) in ameliorating the thermal hypoalgesia in diabetic mice, and the increases in the expression of both total and phosphorylated STAT3 in the DRG of diabetic mice under all these treatment conditions may represent part of INGAP peptide's mechanism of action.
There was a marked increase (about twofold) in the ratio of phosphorylated:total STAT3 in DRG from INGAP peptide-treated control mice (Fig. 3B) . The higher phospho-STAT3 levels in INGAP peptide-treated mice (both control and diabetic) could reflect a priming effect of the peptide that enhances the DRG response to injury, as observed in our in vitro outgrowth assays, which mimic axotomy. The higher STAT3 phosphorylation observed in control mice vs. diabetic mice following INGAP peptide treatment may result from activation of other receptors that afford neuroprotection when signaling to STAT3, such as the IL-6 receptor (IL-6R) (78), the leukemia inhibitory factor (LIF) receptor (LIFR) (79) , or the ciliary neurotrophic factor (CNTF) receptor (CNTFR) (79, 80) . In PC12 cells, a model system of sensory neurons, we have observed a neuroprotective effect of INGAP peptide in a serum-withdrawal paradigm, an effect that appears to be blocked by inhibitors of JAK2 (AG490), MEK (U0126), or PI3K (wortmannin) (unpublished observations). It is conceivable that INGAP peptide may enhance signaling pathways downstream of IL-6, CNTF, or LIF receptors and thus lead to a greater degree of STAT3 phosphorylation.
INGAP peptide administered in vivo enhances mitochondrial activity of sensory ganglia in vitro
The survival of mature sensory neurons is independent of neurotrophins (81), and DRG cultures are able to survive for up to 2 wk in the absence of NGF (82) . We thus examined the relative cell viability of DRG and observed marked increases in cell viability of INGAP peptide-treated diabetic and nondiabetic mice after 7 days in culture (Fig. 4) . Given the magnitude of these increases (20-25%), we attribute them to an increase in the number of nonneuronal cells or possibly an improved overall metabolic status of the cells. This finding suggests a mechanism by which INGAP peptide may exert its effects indirectly in the nervous system, namely by enhancing the availability of trophic factors (including Reg2) from Schwann cells. Such a possibility would imply either increased trophic factor synthesis and release or a redistribution of trophic factor receptors at the cell surface, as previously shown for the receptors for glial-derived neurotrophic factor (GDNF) and transforming growth factor-β (TGF-β) (83).
In conclusion, we have provided evidence that INGAP peptide can exert effects on the peripheral sensory nervous system in vivo. These effects are manifested as improvements in a number of defects that characterize experimental diabetic neuropathy in mice, namely impaired thermal nociception and hyperphosphorylation of neurofilament proteins. In addition, we find that INGAP peptide induces an up-regulation of proteins involved in nerve regeneration (β-IIItubulin, actin, STAT3) that seem to underlie an enhanced regenerative capacity in an in vitro model of axotomy. The beneficial effects on the nervous system of INGAP peptide, a candidate therapeutic for IDDM, are of particular importance given the common clinical finding that diabetic neuropathy, once established, may be essentially irreversible despite correction of the hyperglycemia. Administration of INGAP peptide to diabetic patients may, in addition to restoring glycemic control (22) and age-matched control mice were sacrificed after receiving INGAP (25 mg/kg, i.p., every second day) and/or insulin (0.1 U/day, s.c.) for 2 wk. Dorsal root ganglia were then dissected and cultured as explant cultures in 14 ul of Matrigel (BectonDickinson) in serum-free RPMI-1640 media (Sigma) containing 1% antibiotic for 7 days postsacrifice. At the indicated times, light microscope images were captured using an MCID/M4 imaging system, and nerve outgrowth (total neuritic density, maximal length) was assessed using Adobe Photoshop and NIH Image. A) Total neuritic density assessed over a 7-day period in vitro. B, C) Maximal length measured after 7 days in culture. Data presented are average values of groups of n = 5 ± SE *Significant difference from the nontreated control group (P<0.05) and **significant difference from the nontreated diabetic group (P<0.05). control mice were sacrificed after receiving INGAP and/or insulin for 14 days as previously described. Dorsal root ganglia were then dissected and prepared for Western blotting. A, B) DRG samples were separated by 12% SDS-PAGE, and the expression of phosphorylated and nonphosphorylated proteins was assessed using specific primary antibodies and detection by enhanced chemiluminescence. C) Quantification of major proteins altered by INGAP peptide administration. Data presented are average values of groups of n = 3-4 ± SE *Significant difference from the nontreated control group (P<0.05) and **significant difference from the nontreated diabetic group (P<0.05). Diabetic and age-matched control mice were sacrificed after receiving INGAP and/or insulin for 14 days as previously described. Dorsal root ganglia were then dissected and cultured as explant cultures in 14 ul of Matrigel (BectonDickinson) in serum-free RPMI-1640 media (Sigma) containing 1% antibiotic for 7 days postsacrifice. On the indicated days, the MTT cell viability assay was performed on the DRG explants. Data presented are average values of groups of n = 4-5 ± SE *Significant difference from the nontreated control group (P<0.05) and **significant difference from the nontreated diabetic group (P<0.05).
